alpha fetoprotein

Overview

Alpha-fetoprotein (AFP) is a glycoprotein and well-established serum tumor marker, best known for its clinical association with hepatocellular carcinoma (HCC). It is also used in the evaluation of other AFP-producing malignancies, including alpha-fetoprotein-producing gastric cancer, where elevated serum AFP can correlate with tumor stage and prognosis. In routine practice, AFP is primarily valued as a biomarker for detection, risk stratification, and disease monitoring rather than as a standalone diagnostic test.

Beyond its biomarker role, recent research has increasingly examined AFP as a biologically active molecule in cancer. In hepatocellular carcinoma, AFP has been investigated as a regulator of cancer stemness and tumor progression, including signaling through the PI3K/Akt signaling pathway. This broader functional perspective has prompted studies of AFP in relation to tumor biology, glycoprotein recognition, and assay development, alongside related cancer markers such as carcinoembryonic antigen, epithelial cell adhesion molecule, CD44, Erb-b2 receptor tyrosine kinase 2, and tumor protein p53.

Recent Publications Focus

Below is a summary of the newest research publications targeting alpha fetoprotein (sorted by publication date).

Recent studies have focused heavily on alpha-fetoprotein (AFP) as both a clinical biomarker and an analytical target for highly sensitive detection platforms in hepatocellular carcinoma and related liver cancer applications. Several groups developed biosensors that coupled AFP recognition with signal amplification strategies, including entropy-driven autocatalysis with CRISPR/Cas12a, photonic crystal fluorescence enhancement with microfluidic automation, and neocuproine-boosted Cu-MOF nanozyme colorimetry. These assays reported low detection limits, rapid readouts, and good agreement with clinical reference methods such as ELISA, supporting AFP’s continued use in point-of-care and laboratory-based diagnostic workflows.

Other publications extended AFP detection into dual-mode and multiplexed formats. A DNA tetrahedron-mediated platform on a single gold nanowire combined surface-enhanced Raman scattering and electrochemical readouts for exosome analysis, using CD63-mediated capture together with AFP-mediated signal tagging to improve specificity for HepG2-derived exosomes. The system showed strong clinical discrimination between serum samples from liver cancer patients and healthy volunteers. In a separate glycoprotein biosensor study, AFP was measured using both lectin-based and antibody-based ion-selective electrodes, with heparin polysaccharide used to amplify the potentiometric signal; this work also compared glycan-lectin and antibody recognition of the same AFP target and demonstrated sensitive performance in serum matrices.

Beyond assay development, AFP was also examined as a prognostic and disease-associated marker in cancer biology. One study evaluated log-transformed serum AFP together with des-gamma-carboxy prothrombin for predicting early recurrence after hepatectomy in hepatocellular carcinoma and used these variables to build a nomogram for risk stratification. Another review on alpha-fetoprotein-producing gastric cancer described AFP as a serum tumor marker associated with tumor stage and prognosis, while also noting that intra-tumoral AFP may contribute to invasiveness, metastasis, and immune evasion. The review further highlighted co-elevation of AFP with carcinoembryonic antigen, human chorionic gonadotropin, or PIVKA-II as a sign of high malignant potential and poor prognosis.

Across these publications, AFP was consistently used as a clinically relevant target for improving early diagnosis, risk assessment, and biomarker quantification. The reported methods emphasized signal amplification, simplified sample handling, and compatibility with serum testing, reflecting a broader effort to translate AFP-based assays into practical diagnostic tools for liver disease and cancer screening.

Background PMIDs

• [PMID 41651174]
• [PMID 41978393]

Method PMIDs

• [PMID 42410425]

Result PMIDs

• [PMID 42086808]

Target PMIDs

• [PMID 41764904]
• [PMID 41978393]
• [PMID 42063290]
• [PMID 42132692]
• [PMID 42174235]
• [PMID 42190059]
• [PMID 42335458]
• [PMID 42379778]